Cassava Sciences Inc SAVA
Institutional shares held
15.9 Million
1.26M
calls
791K
puts
Total value of holdings
$43.9M
$3.47M
calls
$2.18M
puts
Market Cap
$111M
40,097,900
Shares Out.
Institutional ownership
39.68%
# of Institutions
136
We take great care to ensure that the data presented and summarized in this overview for CASSAVA SCIENCES INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding SAVA
View all-
Black Rock Inc. New York, NY3.22MShares$8.89 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.29MShares$6.32 Million0.0% of portfolio
-
Marshall Wace, LLP London, X02.06MShares$5.69 Million0.01% of portfolio
-
David A. Siegel Two Sigma Advisers, LP | New York, Ny962KShares$2.65 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY565KShares$1.56 Million0.0% of portfolio
-
Two Sigma Investments, LP New York, NY565KShares$1.56 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA538KShares$1.48 Million0.0% of portfolio
-
Goldman Sachs Group Inc New York, NY473KShares$1.31 Million0.0% of portfolio
-
Gmt Capital Corp Atlanta, GA450KShares$1.24 Million0.06% of portfolio
-
683 Capital Management, LLC New York, NY425KShares$1.17 Million0.07% of portfolio
Latest Institutional Activity in SAVA
Top Purchases
Top Sells
About SAVA
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.
Insider Transactions at SAVA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 24
2025
|
Robert Eugene Anderson Jr Director |
BUY
Open market or private purchase
|
Direct |
8,600
+50.0%
|
$17,200
$2.9 P/Share
|
|
Nov 20
2025
|
Richard Barry President & CEO |
BUY
Open market or private purchase
|
Indirect |
150,000
+13.79%
|
$300,000
$2.76 P/Share
|
|
Nov 19
2025
|
Richard Barry President & CEO |
BUY
Open market or private purchase
|
Indirect |
73,385
+8.52%
|
$146,770
$2.75 P/Share
|
|
Sep 30
2025
|
Robert Christopher Cook Chief Operating & Legal Office |
BUY
Open market or private purchase
|
Direct |
13,725
+50.0%
|
$27,450
$2.91 P/Share
|
|
Sep 22
2025
|
Richard Barry President & CEO |
BUY
Open market or private purchase
|
Indirect |
7,172
+0.99%
|
$14,344
$2.28 P/Share
|
|
Sep 19
2025
|
Richard Barry President & CEO |
BUY
Open market or private purchase
|
Indirect |
47,308
+3.14%
|
$94,616
$2.27 P/Share
|
|
Sep 18
2025
|
Richard Barry President & CEO |
BUY
Open market or private purchase
|
Indirect |
190,633
+11.52%
|
$381,266
$2.19 P/Share
|
|
Nov 29
2024
|
Eric Schoen Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
59,800
-83.87%
|
$179,400
$3.86 P/Share
|
|
Nov 29
2024
|
Eric Schoen Chief Financial Officer |
SELL
Open market or private sale
|
Indirect |
2,000
-100.0%
|
$6,000
$3.82 P/Share
|
|
Nov 29
2024
|
Eric Schoen Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+41.22%
|
$50,000
$1.18 P/Share
|
|
Nov 29
2024
|
James William Kupiec Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
4,000
-100.0%
|
$12,000
$3.87 P/Share
|
|
May 16
2024
|
Sanford Robertson Director |
BUY
Bona fide gift
|
Indirect |
5,000
+50.0%
|
-
|
|
May 16
2024
|
Sanford Robertson Director |
SELL
Bona fide gift
|
Direct |
5,000
-0.52%
|
-
|
|
Apr 26
2024
|
Sanford Robertson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
69,000
+6.73%
|
$1,518,000
$22.0 P/Share
|
|
Apr 23
2024
|
Richard Barry President & CEO |
BUY
Exercise of conversion of derivative security
|
Indirect |
176,085
+27.27%
|
$3,873,870
$22.0 P/Share
|
|
Apr 18
2024
|
James William Kupiec Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+27.27%
|
$33,000
$22.0 P/Share
|
|
Apr 17
2024
|
Eric Schoen Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+6.58%
|
$33,000
$22.0 P/Share
|
|
Aug 23
2023
|
Sanford Robertson Director |
BUY
Open market or private purchase
|
Direct |
30,000
+3.27%
|
$510,000
$17.45 P/Share
|
|
Aug 22
2023
|
Richard Barry President & CEO |
BUY
Open market or private purchase
|
Indirect |
16,571
+5.34%
|
$265,136
$16.65 P/Share
|
|
Aug 21
2023
|
Richard Barry President & CEO |
BUY
Open market or private purchase
|
Indirect |
1,906
+0.68%
|
$30,496
$16.8 P/Share
|
Last 12 Months Summary
Buy / Acquisition
491K
Shares
From
3
Insiders
| Open market or private purchase | 491K shares |
|---|
Sell / Disposition
0
Shares
From
0
Insiders